BioTime Inc. (BTX)

2.13
0.03 1.40
AMEX : Health Technology
Prev Close 2.16
Open 2.15
Day Low/High 2.11 / 2.15
52 Wk Low/High 1.88 / 3.16
Volume 6.71K
Avg Volume 545.00K
Exchange AMEX
Shares Outstanding 126.88M
Market Cap 253.75M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioTime Warrants To Expire On October 1, 2018

BioTime Warrants To Expire On October 1, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, is advising the holders of its publicly traded warrants (NYSE American: BTX.

BioTime Implements New Leadership Structure; Appoints Brian Culley As Chief Executive Officer

BioTime Implements New Leadership Structure; Appoints Brian Culley As Chief Executive Officer

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that the Board of Directors has implemented a new leadership structure under which Brian Culley has been appointed as the...

BioTime Updates Timeline For Distribution Of AgeX Shares To BioTime Shareholders

BioTime Updates Timeline For Distribution Of AgeX Shares To BioTime Shareholders

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors intends to set a new record date for the distribution of AgeX Therapeutics, Inc.

BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence

BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has closed the previously announced transaction with Juvenescence Limited, a global leader in developing therapeutics...

BioTime's CEO Adi Mohanty And CFO Russell Skibsted To Participate In Upcoming Panel And Conferences

BioTime's CEO Adi Mohanty And CFO Russell Skibsted To Participate In Upcoming Panel And Conferences

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer will participate in a panel discussion at the Annual B.

AgeX Therapeutics Acquires Technology To Regulate Immune Tolerance

AgeX Therapeutics Acquires Technology To Regulate Immune Tolerance

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc.

BioTime To Present Data At The Military Health System Research Symposium

BioTime To Present Data At The Military Health System Research Symposium

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will be presenting a poster at the Military Health System Research Symposium (MHSRS) from August 20-23, 2018 in Kissimmee,...

BioTime Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the second quarter ended June 30, 2018 and recent corporate accomplishments.

BioTime To Receive $43 Million From Juvenescence

BioTime To Receive $43 Million From Juvenescence

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced a new strategic alignment between AgeX Therapeutics and Juvenescence Limited, a global leader in developing therapeutics focused...

BioTime Announces The Start Of An Investigator Initiated Study Of Premvia™ Designed And Conducted By Dr. Gordon H. Sasaki

BioTime Announces The Start Of An Investigator Initiated Study Of Premvia™ Designed And Conducted By Dr. Gordon H. Sasaki

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported that Gordon H.

BioTime Announces Distribution Ratio For Distribution Of AgeX Therapeutics Shares

BioTime Announces Distribution Ratio For Distribution Of AgeX Therapeutics Shares

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the distribution ratio for the distribution of AgeX Therapeutics shares owned by BioTime on a...

Data From BioTime's OpRegen® Program To Be Presented At AAO 2018

Data From BioTime's OpRegen® Program To Be Presented At AAO 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its abstract "PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD...

BioTime To Announce Second Quarter 2018 Results On August 2, 2018

BioTime To Announce Second Quarter 2018 Results On August 2, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release second quarter 2018 financial and operating results on Thursday, August 2, 2018, after the close of the U.

BioTime Announces July 31, 2018 Record Date For The Distribution Of AgeX Therapeutics Shares

BioTime Announces July 31, 2018 Record Date For The Distribution Of AgeX Therapeutics Shares

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the record date for the distribution of AgeX Therapeutics ("AgeX") shares owned by BioTime on...

BioTime Awarded Grant From The NIH

BioTime Awarded Grant From The NIH

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has been awarded a grant of $743,345 from the Small Business Innovation Research (SBIR) program of the National Institutes...

BioTime Licenses GMP Cell Line To Goliver Therapeutics

BioTime Licenses GMP Cell Line To Goliver Therapeutics

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver Therapeutics, a France-based company focused on addressing liver diseases with...

AgeX Therapeutics Closes On $5 Million Strategic Investment From Juvenescence

AgeX Therapeutics Closes On $5 Million Strategic Investment From Juvenescence

AgeX Therapeutics, Inc., a subsidiary of  BioTime, Inc.

BioTime Announces Submission Of Draft Registration Statement For A Proposed Distribution Of Its AgeX Shares

BioTime Announces Submission Of Draft Registration Statement For A Proposed Distribution Of Its AgeX Shares

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration statement on Form 10 was submitted to the U.

AgeX Therapeutics Appoints John F. Mauldin To Board Of Directors

AgeX Therapeutics Appoints John F. Mauldin To Board Of Directors

AgeX Therapeutics, Inc., a subsidiary of  BioTime, Inc.

BioTime Announces $1.9 Million Grant For Continued Development Of OpRegen® For Dry-AMD

BioTime Announces $1.9 Million Grant For Continued Development Of OpRegen® For Dry-AMD

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.

BioTime Further Expands OpRegen® Clinical Trial In Dry-AMD With The Opening Of Two Additional U.S. Sites

BioTime Further Expands OpRegen® Clinical Trial In Dry-AMD With The Opening Of Two Additional U.S. Sites

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen ®, with the addition of two new U.

BioTime Reports First Quarter Results And Recent Corporate Accomplishments

BioTime Reports First Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the first quarter ended March 31, 2018 and recent corporate accomplishments.

AgeX Announces NIH Grant Award

AgeX Announces NIH Grant Award

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc.

BioTime Presents Updated OpRegen® Clinical Trial Data At ARVO

BioTime Presents Updated OpRegen® Clinical Trial Data At ARVO

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that an abstract related to one of its lead programs, OpRegen ® for dry-AMD, was presented at the Association for Research in...

BioTime To Announce First Quarter 2018 Results On May 10, 2018

BioTime To Announce First Quarter 2018 Results On May 10, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release first quarter 2018 financial and operating results on Thursday, May 10, 2018, after the close of the U.

TheStreet Quant Rating: D (Sell)